Benign Prostatic Hyperplasia Hesi Case Study

Benign Prostatic Hyperplasia HESI Case Study: A Comprehensive Clinical Walkthrough

A 68‑year‑old male presents to the outpatient clinic with a three‑month history of nocturia, weak urinary stream, and a sensation of incomplete bladder emptying. Laboratory studies reveal a normal creatinine level and a prostate‑specific antigen (PSA) of 1.So his medical history includes hypertension and type 2 diabetes mellitus, both well‑controlled with medication. On digital rectal examination the prostate is enlarged, smooth, and non‑tender. Think about it: 8 ng/mL. This benign prostatic hyperplasia hesi case study is designed to test your ability to recognize the typical presentation, perform appropriate diagnostic work‑up, and formulate a patient‑centered management plan for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) And that's really what it comes down to..

IntroductionBenign prostatic hyperplasia, also known as hyperplasia prostatica in Latin, is a non‑malignant proliferation of prostatic stromal and epithelial cells that commonly affects men over the age of 50. The condition can lead to obstructive and irritative urinary symptoms that significantly impact quality of life. In nursing and health‑sciences curricula, a benign prostatic hyperplasia hesi case study often serves as a clinical reasoning exercise, requiring students to integrate anatomy, pathophysiology, pharmacology, and nursing interventions.

Case Presentation

Patient Demographics and Chief Complaint

• Age: 68 years
• Sex: Male
• Chief complaint: Nocturia (waking up twice nightly to void), weak urinary stream, and feeling of residual bladder fullness.

History of Present Illness

• Onset: Gradual, over the past three months.
• Progression: Symptoms have slowly worsened, prompting the patient to seek medical attention.
• Associated symptoms: No dysuria, hematuria, or flank pain.
• Impact: Sleep disruption due to nocturia, leading to daytime fatigue.

Past Medical History

• Hypertension (controlled with lisinopril)
• Type 2 diabetes mellitus (controlled with metformin)
• No prior history of urinary tract infections or prostate surgery.

Medications

• Lisinopril 10 mg daily
• Metformin 500 mg twice daily
• Over‑the‑counter antihistamine (occasionally for seasonal allergies)

Family History

• Father: Hypertension, died at 78 from myocardial infarction.
• Mother: Alive, with unknown urologic history.
• Siblings: No known hereditary conditions.

Diagnostic Evaluation

Laboratory Tests

• Urinalysis: Negative for leukocytes, nitrites, and blood.
• Serum PSA: 1.8 ng/mL (within normal age‑adjusted range).
• Complete Blood Count (CBC): Normal.
• Basic Metabolic Panel (BMP): Normal renal function.

Imaging Studies

• Transrectal ultrasound (TRUS): Demonstrates an enlarged prostate with a volume of approximately 45 cm³, homogeneous echotexture, and no discrete nodules.
• Post‑void residual (PVR) volume: Measured by bladder scan at 150 mL (elevated).

Functional Assessment

• International Prostate Symptom Score (IPSS): 18, indicating moderate LUTS. - Quality of Life (QoL) score: 4 (moderate impact).

Differential Diagnosis

1. Benign Prostatic Hyperplasia (BPH) – Most likely given the clinical picture, age, and imaging findings.
2. Prostate Cancer – Ruled out by normal PSA and absence of suspicious nodules on TRUS.
3. Urinary Tract Infection (UTI) – Excluded by negative urinalysis.
4. Bladder Obstruction from Strictures – Unlikely without history of intermittent catheterization or prior pelvic surgery.

Management Strategies

Pharmacologic Therapy

• Alpha‑1 blockers (e.g., tamsulosin) – First‑line to relax smooth muscle in the prostate and bladder neck, improving urine flow.
• 5‑α‑reductase inhibitors (e.g., finasteride) – Considered if prostate volume >30 cm³ or symptoms persist after alpha‑blocker therapy.
• Phosphodiesterase‑5 inhibitors (e.g., tadalafil) – May provide dual benefit for LUTS and erectile dysfunction.

Surgical Options (if medical therapy fails)

• Transurethral resection of the prostate (TURP) – Gold standard for large‑volume BPH.
• Laser enucleation (HoLEP) – Minimally invasive alternative with comparable outcomes.
• Prostatic urethral lift (Urolift) – Preserves ejaculatory function and is associated with quicker recovery.

Nursing Care Plan

Assessment

• Monitor urinary output, PVR volumes, and symptom progression using validated scales (IPSS, QoL).
• Assess for side effects of medications, especially orthostatic hypotension from alpha‑blockers.
• Evaluate patient’s knowledge of disease and treatment expectations.

Diagnosis

• Risk for decreased renal perfusion related to obstructive urinary symptoms as evidenced by elevated PVR and nocturia.

Planning

• Establish realistic goals: reduce nocturia to ≤1 episode per night within 4 weeks, improve PVR to <100 mL, and enhance QoL scores.

Implementation

• Medication Administration:
  1. Administer tamsulosin 0.4 mg daily as prescribed.
  2. Educate patient on taking the medication after the same meal each day to maintain steady plasma levels. - Bladder Training:
  • Encourage timed voiding every 2

Implementation (continued)

• Fluid‑timing strategy: Instruct the patient to limit evening fluid intake to 250 mL after 6 p.m., encouraging a gradual shift of the diurnal pattern toward earlier voids.
• Pelvic‑floor strengthening: Introduce a supervised Kegel regimen, emphasizing slow, sustained contractions performed three times daily to improve bladder neck support and reduce urgency.
• Symptom diary: Provide a structured log sheet for recording void frequency, nocturnal episodes, and any episodes of urgency; review entries during each clinic visit to identify trends and adjust therapy promptly. - Medication monitoring: Schedule a follow‑up appointment 6 weeks after initiating tamsulosin to reassess IPSS, QoL, and PVR; if the PVR remains >150 mL or symptoms persist, consider adding finasteride or discussing minimally invasive surgical alternatives.
• Education on adverse effects: Counsel the patient about potential dizziness or orthostatic symptoms, advising to rise slowly from seated positions and to report any syncope immediately.
• Coordination with allied health: Arrange a brief consultation with a physiotherapist specializing in urologic rehabilitation to reinforce proper voiding techniques and to address any psychosocial concerns related to chronic nocturia.

Evaluation - At the 6‑week reassessment, the patient reports a reduction in nocturnal voids from three to one per night and a modest decline in IPSS from 18 to 13, reflecting improved symptom burden.

• PVR has decreased to 95 mL on repeat bladder scan, indicating adequate bladder emptying.
• QoL score improves from 4 to 2, suggesting a more favorable impact on daily life.
• No orthostatic symptoms have been documented, and laboratory studies remain within normal limits.
• Ongoing monitoring will continue at 3‑month intervals, with a plan to taper or discontinue therapy if sustained symptom control is achieved.

Conclusion The comprehensive approach — integrating pharmacologic optimization, targeted lifestyle modifications, and structured nursing oversight — has effectively mitigated the patient’s lower‑urinary‑tract symptoms and restored a more acceptable voiding pattern. By maintaining vigilant surveillance, educating the patient on self‑management strategies, and promptly addressing any emerging complications, the care team ensures not only symptom relief but also long‑term urologic health. This model exemplifies how collaborative, evidence‑based interventions can transform chronic prostate‑related discomfort into a manageable, quality‑enhancing experience for the individual.

This case highlights the importance of a holistic and patient-centered approach to managing lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). While tamsulosin provided initial relief, the true success stemmed from the integrated plan encompassing pharmacological intervention, behavioral adjustments, and ongoing monitoring. The patient's positive response underscores the efficacy of a multi-modal strategy, moving beyond simply treating the symptoms to addressing the underlying physiological and psychosocial factors influencing voiding patterns Which is the point..

The gradual reduction in nocturnal voids and improvement in quality of life are particularly noteworthy. This demonstrates that even with chronic conditions like BPH, significant improvements in patient well-being are attainable. Plus, the emphasis on patient education regarding potential adverse effects and the proactive coordination with allied health professionals further reinforced the commitment to comprehensive care. This collaborative approach ensures the patient is empowered to actively participate in their own management, fostering a sense of control and promoting adherence to the treatment plan.

Looking ahead, continued monitoring and periodic reassessments will be crucial to ensure sustained symptom control and to adapt the treatment strategy as needed. The bottom line: this case serves as a compelling illustration of how a well-coordinated, evidence-based, and patient-focused management strategy can effectively address the complexities of BPH and significantly improve the quality of life for affected individuals. The plan to potentially taper or discontinue tamsulosin once sustained improvement is achieved reflects a commitment to minimizing long-term medication exposure. Further research exploring the long-term outcomes of this integrated approach and its cost-effectiveness would be valuable in refining best practices for BPH management.